 Rockwell Medical Inc NASDAQ: RMTI has provided the FDA with the supplemental data requested by the agency in December 2021 for its pending Investigational New Drug IND application of Ferric Pyrophosphate Citrate FPC for iron deficiency. The IND supports the proposed Phase 2. 